Interrogating the genome to understand oestrogen-receptor-mediated transcription
- PMID: 18377699
- DOI: 10.1017/S1462399408000653
Interrogating the genome to understand oestrogen-receptor-mediated transcription
Abstract
Defining transcription mediated by the oestrogen (estrogen) receptor (ER) in breast cancer cell models has been an area of interest for many years. Initial studies focused on promoter regions of putative target genes and revealed significant insight into the basis of ER binding to DNA. More recently, the complexities of ER transcription are starting to become apparent. It is now clear that ER can regulate gene targets from significant distances and that cooperating transcription factors play an integral role in ER activity. It is also clear that the sequence information defining an in vivo ER-binding site is more complicated than initially thought. However, contemporary genomic tools based on chromatin immunoprecipitation (ChIP) - such as ChIP-on-chip and ChIP-sequencing - and gene expression profiling have allowed us to redefine the underlying properties of ER biology on a genomic scale. The advances in technology that have permitted a better understanding of how and where ER can bind to DNA are discussed in this review. The possible clinical implications of these findings for understanding the role of oestrogen in breast cancer are also briefly considered.
Similar articles
-
Genome-wide mapping of estrogen receptor-beta-binding regions reveals extensive cross-talk with transcription factor activator protein-1.Cancer Res. 2010 Jun 15;70(12):5174-83. doi: 10.1158/0008-5472.CAN-09-4407. Epub 2010 May 25. Cancer Res. 2010. PMID: 20501845
-
pRb2/p130-E2F4/5-HDAC1-SUV39H1-p300 and pRb2/p130-E2F4/5-HDAC1-SUV39H1-DNMT1 multimolecular complexes mediate the transcription of estrogen receptor-alpha in breast cancer.Oncogene. 2003 Jun 5;22(23):3511-7. doi: 10.1038/sj.onc.1206578. Oncogene. 2003. PMID: 12789259
-
Cofactor competition between the ligand-bound oestrogen receptor and an intron 1 enhancer leads to oestrogen repression of ERBB2 expression in breast cancer.Oncogene. 2000 Jan 27;19(4):490-7. doi: 10.1038/sj.onc.1203416. Oncogene. 2000. PMID: 10698518
-
Genomic actions of estrogen receptor alpha: what are the targets and how are they regulated?Endocr Relat Cancer. 2009 Dec;16(4):1073-89. doi: 10.1677/ERC-09-0086. Epub 2009 Jul 23. Endocr Relat Cancer. 2009. PMID: 19628648 Review.
-
Estrogen receptor target gene: an evolving concept.Mol Endocrinol. 2006 Aug;20(8):1707-14. doi: 10.1210/me.2005-0334. Epub 2006 Jan 5. Mol Endocrinol. 2006. PMID: 16396959 Review.
Cited by
-
Neuroprotective actions of estradiol and novel estrogen analogs in ischemia: translational implications.Front Neuroendocrinol. 2011 Aug;32(3):336-52. doi: 10.1016/j.yfrne.2010.12.005. Epub 2010 Dec 14. Front Neuroendocrinol. 2011. PMID: 21163293 Free PMC article. Review.
-
The gad2 promoter is a transcriptional target of estrogen receptor (ER)alpha and ER beta: a unifying hypothesis to explain diverse effects of estradiol.J Neurosci. 2009 Jul 8;29(27):8790-7. doi: 10.1523/JNEUROSCI.1289-09.2009. J Neurosci. 2009. PMID: 19587286 Free PMC article.
-
Chromosome-wide analysis of protein binding and modifications.Methods Mol Biol. 2009;590:223-33. doi: 10.1007/978-1-60327-378-7_14. Methods Mol Biol. 2009. PMID: 19763507 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources